Abaloparatide to Treat Alveolar Bone Loss for Dental Implant Reconstruction

Abstract

Systemic administration of ABL significantly reduces the risk of fragility fractures in the femur, hip, and vertebrae, but no data exists on the likely positive effects that could be exerted on alveolar bone of the jaws. Considering the mechanism of action in which ABL directly influences osteoblastic cell lines and the previous clinical data reporting a substantial treatment effect of TPD in the regeneration of periodontal defects, the osteoanabolic effect of ABL could be leveraged to enhance procedures that aim to regenerate alveolar bone. The preclinical investigations in the present report evaluate the potential of systemic ABL therapy to increase alveolar bone formation and bone mineral density (BMD), in applications of tooth extraction socket healing, implant osseointegration, and peri-implant regeneration. A series of two experiments were performed in female, Sprague-Dawley rats to assess the effects of ABL under conditions simulating: 1) osteoporosis, in animals that received ovariectomy surgery to induce bone loss via estrogen-deficiency and; 2) in healthy, young animals with normal bone metabolism. These experiments assess the biologic possibility that ABL may increase alveolar bone quality prior to implant placement, enhance primary dental implant fixation, and accelerate healing in dental implant therapy.